Adagene Inks Third Cancer Trial Collaboration With Merck

  • Adagene Inc ADAG has entered into a third clinical trial collaboration and supply agreement with Merck & Co Inc MRK.
  • The agreement includes an open-label, dose-escalation, and expansion clinical study of ADG106 combined with Merck's Keytruda (pembrolizumab) in advanced or metastatic solid and/or hematological malignancies.
  • ADG106 is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb developed to treat advanced solid tumors and non-Hodgkin's lymphoma. 
  • Related: Adagene To Test Its Anti-CTLA-4 Antibodies In Combination With Keytruda In Solid Tumors.
  • Price Action: ADAG shares closed 4.02% lower at $17.80 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsSmall CapGeneralBriefsoncology
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!